FDA lists four new drugs mentioned in Paragraph IV ANDAs

The FDA is out with a list of four new drug products for which the Office of Generic Drugs has received an ANDA containing a Paragraph IV patent certification, meaning the filer contends that a patent listed in the Orange Book either is invalid or unenforceable or will not be infringed by a proposed generic product.

The newly listed drugs: Teva's (TEVA) Treanda, Bausch & Lomb's (VRX) Bepreve and Prolensa, and Forest Labs' (FRX) Namenda XR.

FDA release with link to full .pdf list

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs